Search Results - "Landers, Greg A."

Phase Ib, international, dose-escalation study to evaluate the safety, pharmacokinetics (PK) and efficacy of ST-617 for the attenuation of oral mucositis (OM) in patients receiving chemoradiation (CRT) for head and neck (H&N) cancer by Osei-Fofie, Daniel, Wetter, Julie, Landers, Greg A., Kraus, Peter Alfred, Sukumaran, Shawgi, Mun, Hui, Stein, Brian N., Bray, Victoria Jane, Framroze, Bomi, Gelfand, Jeffrey, Song, Paul Y., Lategan, Andries, Dimitriu, Mikaela, Sonis, Stephen T.

“…Abstract only 6075 Background: OM is a common, painful, and costly toxicity associated with cytotoxic regimens used to treat H&N cancers, which may result in…”
Get full text

Pembrolizumab (pembro) in microsatellite instability-high (MSI-H) advanced gastric/gastroesophageal junction (G/GEJ) cancer by line of therapy by Chao, Joseph, Fuchs, Charles S., Shitara, Kohei, Tabernero, Josep, Muro, Kei, Van Cutsem, Eric, Bang, Yung-Jue, De Vita, Ferdinando, Landers, Greg A., Yen, Chia-Jui, Chau, Ian, Elme, Anneli, Lee, Jeeyun, Ozguroglu, Mustafa, Catenacci, Daniel V.T., Li, Xiaodong, Shih, Chie-Schin, Shah, Sukrut, Bhagia, Pooja, Wainberg, Zev A.

“…Abstract only 430 Background: Pembro has demonstrated promising antitumor activity in patients (pts) with advanced G/GEJ cancer with PD-L1 CPS ≥1 and CPS ≥10…”
Get full text